Morphine and hydromorphone-induced hyperalgesia in a hospice patient

Journal of Palliative Medicine

Volumn 16, Issue 7, 2013, Pages 809-812

  Juba, Katherine M ^a   Wahler, Robert G ^b   Daron, Susan M ^c  

^a ST JOHN FISHER COLLEGE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c Medical Letter   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; DRUG METABOLITE; FENTANYL; GABAPENTIN; HYDROMORPHONE; HYDROMORPHONE 3 GLUCURONIDE; IBUPROFEN; INFUSION FLUID; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE SULFATE; NORTRIPTYLINE; OXYCODONE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; ALLODYNIA; BEDTIME DOSAGE; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER STAGING; CASE REPORT; DISEASE SEVERITY; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HOSPICE PATIENT; HOSPITAL DISCHARGE; HUMAN; HYPERALGESIA; LOW BACK PAIN; LUNG NON SMALL CELL CANCER; MYOCLONUS; NEUROPATHIC PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPIOID INDUCED HYPERALGESIA; PAIN ASSESSMENT; PATIENT CONTROLLED ANALGESIA; PATIENT MONITORING; PATIENT TRANSPORT; PERIPHERAL EDEMA; REVIEW;

ADULT; ANALGESICS, OPIOID; CARCINOMA, NON-SMALL-CELL LUNG; DELAYED-ACTION PREPARATIONS; FEMALE; FENTANYL; HOSPICE CARE; HUMANS; HYDROMORPHONE; HYPERALGESIA; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MORPHINE; NEOPLASM METASTASIS; PAIN MANAGEMENT; PALLIATIVE CARE;

EID: 84880453385     PISSN: 10966218     EISSN: 15577740     Source Type: Journal    
DOI: 10.1089/jpm.2011.0502     Document Type: Review

References (24)

1. Hemstapat K, Monteith GR, Smith D, Smith MT: Morphine-3-glucuronide's neuro-excitatory effects are mediated via indirect activation of N-methyl-D-aspartic acid receptors: Mechanistic studies in embryonic cultured hippocampal neurones. Anesth Analg 2003;97:494-505
2. Smith MT: Neuroexcitatory effects of morphine and hydromorphone: Evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol 2000;27:524-528
3. Wright AWE, Mather LE, Smith MT: Hydromorphone-3-glucuronide a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci 2001;69:409-420
4. Nagar S, Raffa RB: Looking beyond the administered drug: Metabolites of opioid analgesics. J Family Pract 2008;57: S25-S32
5. Thwaites D, McCann S, Broderick P: Hydromorphone neuroexcitation. J Palliat Med 2004;7:545-550
6. Fishbain DA, Cole B, Lewis JE, Gao J, Rosomoff RS: Do opioids induce hyperalgesia in humans? An evidence-based structured review. Pain Med 2009;10:829-839
7. Ossipov MH, Lai J, King T, Vanderah TW, Porreca F: Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure. Biopolymers 2005;80:319-324
8. Sjogren P, Jensen NH, Jensen TS: Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists. Pain 1994;59: 313-316
9. DuPen A, Shen D, Ersek M: Mechanisms of opioid induced tolerance and hyperalgesia. Pain Manage Nurs 2007;8:113-121
10. Smith MT, Watt JA, Cramond T: Morphine-3-glucuronide: A potent antagonist of morphine analgesia. Life Sci 1990;47: 579-585
11. Sjogren P, Thunedborg LP, Christrup L, Hansen SH, Franks J: Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administration? Six case histories. Acta Anaesthesiol Scand 1998; 42:1070-1075
12. Parisod E, Siddall PJ, Viney M, McClelland JM, Cousins MJ: Allodynia after acute intrathecal morphine administration in a patient with neuropathic pain after spinal cord injury. Anesth Analg 2003;97:183-186
13. Smith MT, Wright AWE, Williams BE, Stuart G, Cramond T: Cerebrospinal fluid and plasma concentrations of morphine, morphine-3-glucuronide, and morphine-6-glucuronide in patients before and after initiation of intracerebroventricular morphine for cancer pain management. Anesth Analg 1999; 88:109-116
14. Patel S, Roshan VR, Lee KC, Cheung RJ: A myoclonic reaction with low-dose hydromorphone. Ann Pharmacother 2006;40:2068-2070
15. Chung KS, Carson S, Glassman D, Vadivelu N: Successful treatment of hydromorphone-induced neurotoxicity and hyperalgesia. Conn Med 2004;68:547-549
16. Forero M, Chan PSL, Restrepo-Garces CE: Successful reversal of hyperalgesia/myoclonus complex with low-dose ketamine infusion. Pain Pract 2012;12:154-158
17. Mercadante S: Opioid rotation for cancer pain: Rationale and clinical aspects. Cancer 1999;86:1856-1866
18. Macdonald N, Der L, Allan S, Champion P: Opioid hyperexcitability: The application of alternate opioid therapy. Pain 1993;53:353-355
19. Olesen AE, Staahl C, Arendt-Nielsen L, Drewes AM: Different effects of morphine and oxycodone in experimentally evoked hyperalgesia: A human translational study. Br J Clin Pharmacol 2010;70:189-200
20. Mao J, Price DD, Mayer DI: Thermal hyperalgesia in association with the development of morphine tolerance in rats: Roles of excitatory amino acid receptors and protein kinase C. J Neurosci 1994;14:2301-2312
21. Mao J, Sung B, Ji RR, Lim G: Chronic morphine induces down regulation of spinal glutamate transporters: Implications in morphine intolerance and abnormal pain sensitivity. J Neurosci 2002;22:8312-8323
22. Trujillo KA, Akil H: Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801.Science 1991;251:85-87
23. Marek P, Ben-Eliyahu S, Gold M, Liebeskind JC: Excitatory amino acid antagonists (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the rate. Brain Res 1991;547:77-81
24. Bruera E, Sweeney C: Methadone use in cancer patients with pain: A review. J Palliat Med 2002;5:127-138